Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous adipose-derived mesenchymal stem cells (Xinhua Hospital)
- Development stage
- Unknown
- Lead developer
- Xinhua Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intracranial
01
Overview
This investigational autologous cell therapy, developed by Xinhua Hospital at the Shanghai Jiao Tong University School of Medicine, utilizes adipose-derived mesenchymal stem cells (ADSCs) for the treatment of facial and auditory nerve injuries. The therapy is specifically being evaluated for patients with hemifacial spasm who experience cranial nerve dysfunction following microvascular decompression (MVD) surgery. The process involves harvesting the patient's own adipose tissue, isolating the mesenchymal stem cells, and transplanting them directly to the site of the injured facial or auditory nerve during the surgical procedure. The goal of the therapy is to promote neural regeneration and functional recovery through the neuroprotective and regenerative properties of the stem cells, potentially offering a superior recovery profile compared to standard pharmacological treatments.
- Other names
- autologous adipose stem cell therapyautologous adipose-derived mesenchymal stem cellsADSCsAutologous Adipose Stem Cells for Facial Nerve Injury in Hemifacial Spasm
Beyond the preview
Go deeper on autologous adipose-derived mesenchymal stem cells (Xinhua Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous adipose-derived mesenchymal stem cells (Xinhua Hospital).